Objective: The transcription factor nuclear factor 3BAB (NF-3BAB) promotes cell survival and radioresistance in head and neck squamous cell carcinoma (HNSCC). Our objective was to study bortezomib, a small-molecule inhibitor of proteasome activity that disrupts the degradation of inhibitor 3BAB (I3BAB) and activation of NF-3BAB, for potential cytotoxic and radiosensitizing activity in recurrent HNSCC.
Design: During a dose-escalation phase 1 clinical trial, clinical effects of proteasome inhibition and antitumor response were evaluated. Serial tumor biopsy specimens were collected before and 24 hours after bortezomib treatment alone, and immunohistochemical staining of p65NF-kB and other biomarkers was conducted.
Allen CT, Chen Z, Van Waes C. P197 Combining the Proteasome Inhibitor Bortezomib With Reirradiation in Patients With Recurrent Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(8):903. doi:10.1001/archotol.132.8.903-b